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Evans syndrome (ES) is an autoimmune disorder characterized by simultaneous or sequential devel-
opment of autoimmune hemolytic anemia, immune thrombocytopenia, and/or neutropenia. ES can be
classiﬁed as a primary (idiopathic) or secondary (associated with an underlying disease) syndrome. We
report a case of ES in an elderly patient in the presence of multiple trigger factors such as recent
inﬂuenza vaccine, marginal zone lymphoma, and neuroendocrine tumor G1. Whether this association is
casual or causal remains a matter of speculation. It is however necessary to have a thorough work-up in a
newly diagnosed ES and a more accurate search of miscellaneous factors especially in elderly patients.
Copyright  2014, Taiwan Society of Geriatric Emergency & Critical Care Medicine. Published by Elsevier
Taiwan LLC. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).1. Introduction
Evans syndrome (ES) includes acquired autoimmune, hemolytic
anemia, and thrombocytopenia and has been described very
recently1,2. It is more frequent in adult women and has usually been
reported during pregnancy. We report a case of ES in an elderly
patient in the presence of multiple trigger factors such as recent
inﬂuenza vaccine, marginal zone lymphoma, and neuroendocrine
tumor G1.
2. Case report
A 73-year-old female presented to the emergency department
(ED) complaining of malaise, asthenia, dyspnea on mild effort, and
emission of hypercromic urine occurring 7 days after administra-
tion of the inﬂuenza vaccine. The medical history of the patientated to the manuscript.
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es/by-nc-nd/4.0/).included diabetes mellitus, chronic obstructive pulmonary disease,
hypertension, and hypothyroidism, and her usual medications
consisted of an oral hypoglycemic agent (sitagliptin), antihyper-
tensive medications (losartan plus hydrochlorothiazide), L-
thyroxine, and long-acting b agonist (indacaterol). Steroid treat-
ment (prednisone 25 mg per os) was initially started at home
without any improvement. At admission, her vital signs were
normal and the patient was not in acute distress; her heart, lungs,
and abdominal examinations were unremarkable, except for mild
splenomegaly, and she had no evidence of lymphoadenopathy or
signs of bleeding diathesis. The preliminary laboratory tests
revealed a white blood cell (WBC) count of 6.7 x 109/L, hemoglobin
(Hb) of 8.4 g/L, hematocrit of 25.5%, and platelet count (PLT) of
252 x 109/L, elevated values of lactate dehydrogenase (980 U/L),
consumed haptoglobin, and direct antiglobulin test anti-IgG posi-
tive. Furthermore, laboratory tests showed normal values of liver
function, prothrombin time (PT), partial thromboplastin time (PTT),
serum protein electrophoresis, serum immunoglobulin concentra-
tion, and negativity of antinuclear antibodies, HIV, hepatitis A, B,
and C serology tests.
After hematological consultation, we started therapy with oral
prednisone 1 mg/kg plus intravenous immunoglobulin (IVIG) oficine. Published by Elsevier Taiwan LLC. This is an open access article under the CC
D. D’Ambrosio et al.2380.6 g/kg daily, with a gradual increase of hemoglobin count to 9.4 g/
dL at the 8th day (Table 1). Beginning on the 10th day, we observed
a rapid decrease in platelet counts at the 20th day (21 k/mL). The
laboratory ﬁndings revealed the presence of platelet antigen-
speciﬁc antibodies, and a normal peripheral blood smear
excluded pseudothrombocytopenia. At the 20th day, administra-
tion of prednisonewas stopped and dexamethasone plus IVIG 0.6 g/
kg for 5 days was intravenously administered. At the 25th day, oral
prednisone was administered. Bone marrow aspirate and core bi-
opsy (Fig. 1A and B) showed hypercellular marrow with nodular
and paratrabecular inﬁltration of small B lymphocytes. Immuno-
phenotypic analysis of peripheral blood showed a monoclonal B
lymphocyte CD20þCD5eCD10e population (Fig. 1C), compatible
with marginal zone lymphoma. The ultrasound examination
showed mild splenomegaly with no other abnormalities. The
abdominal computed tomographic (CT) scan revealed a neo-
formation on the endoluminal side of the duodenum near the
papilla of Vater. Esophagogastroduodenoscopy and biopsy
conﬁrmed the presence of a polypoid lesion at the second portion
of the duodenum, with histological ﬁndings indicating a neuroen-
docrine tumor (NET) G1. Chromogranin A was 363 ng/mL (normal
between 20 ng/mL and 100 ng/mL), whereas all other hormones
were within normal limits, including urinary 5-hydroxyindolo-
acetic acid. Anterior planar view of the abdomen 24 hours and 48
hours after injection of 120 MBq 111I Pentetreotide (octreoscan)
was strongly suggestive of high amounts of somatostatin receptors
in the duodenum. The oncologist decided to follow-up NETwithout
starting therapy while the hematologist suggested close moni-
toring for indolent lymphoma. Laboratory tests at the time of
discharge revealed:WBC 10.5 k/mL, Hb 12.9 g/dL, Hct 40.4%, and PLT
334 k/mL.
3. Discussion
ES is an autoimmune disorder deﬁned by the simultaneous or
sequential development of autoimmune hemolytic anemia (AIHA),
immune thrombocytopenia (ITP), and/or immune neutropenia1,2.
Since ﬁrst described in the early 1950s, ES has long been considered
as a rather incidental and “anecdotal” combination of ITP and AIHA
and/or autoimmune neutropenia in the absence of any underlying
cause. The largest survey of ES published to date reviewed 68 pa-
tients with a mean age of 52  33 years3. In this study, ES was
considered idiopathic in 34 patients but an underlying disorder,
such as systemic lupus erythematosus, lymphoproliferative disor-
ders, or primary immunodeﬁciences, was detected in half of these
cases3. We also found a report of ES following inﬂuenza vaccine4, as
well as its association with miscellaneous diseases such asTable 1
Correlation between clinicalelaboratoristic course and treatment.
Day of
hospitalization
Hb level
(g/dL)
Platelet
count (k/mL)
Therapy
1st 8.4 308 Prednisone
75 mg þ IVIG 0.6 g/kg
8th 9.4 267 Prednisone 50 mg
10th 9.9 128 Prednisone 50 mg
15th 10.8 54 Prednisone 50 mg
20th 9.2 21 Dexamethasone
40 mg þ IVIG 0.6 g/kg
25th 9.9 27 Prednisone 75 mg
30th 10.8 28 Prednisone 75 mg
35th 11.5 28 Prednisone 75 mg
40th 11.2 64 Prednisone 50 mg
45th 12.4 140 Prednisone 37.5 mg
50th 12.5 241 Prednisone 37.5 mg
60th 12.9 334 Prednisone 25 mg
IVIG ¼ intravenous immunoglobulin.
Fig. 1. Morphological analysis of sections of bone marrow revealed nodular and par-
atrabecular inﬁltration of small B lymphocyte (A, B), whereas immunophenotypic
analysis (C) with fast red chromogen for CD20 antigen showed a monoclonal B
lymphocyte CD20þCD5eCD10e population (C), compatible with marginal zone
lymphoma.enterochromafﬁn-like tumor5. ES is more than a coincidental
combination of immune cytopenias, but rather a chronic state of
profound dysregulation of the immune system that may be asso-
ciated with other autoimmune or lymphoproliferative disorders as
well as primary immunodeﬁciencies6. Corticosteroids remain the
cornerstone of treatment, with an initially large response (80%), but
eventually up to two-thirds of patients are provided with at least
one second-line treatment, mostly to spare corticosteroids. IVIG
represents another ﬁrst-step therapy, especially in the presence of
ITP. As a second-line treatment, rituximab is now worth consid-
ering before splenectomy and/or the use of immunosuppressors in
patients who have a chronic and corticosteroid-dependent ES;
splenectomy, danazol-speciﬁc immunosuppressants (intravenous
Trigger Factors and Evans Syndrome in the Elderly 239cyclophosphamide, cyclosporin, or azathioprine) andmore recently
mycophenolate mofetil represent alternative strategies7.
In our case report, we found multiple factors that could trigger
ES, such as inﬂuenza vaccine, indolent lymphoma, and NET.
To the best of our knowledge, this is the ﬁrst case of ES associ-
ated with concomitant multiple trigger factors. Whether this as-
sociation is casual remains a matter of speculation. Immunizations
and lymphoproliferative disorders may provide a trigger for the
development of autoimmune disease in susceptible individuals,
such as in an elderly patient8. Marginal zone B cells have been
shown to initiate immune responses by transporting IgM antigen
immune complexes into the follicle9. This mechanism may play an
important role in the removal of senescent cells, apoptotic debris,
and immune complexes9. A migration of neoplastic cells with im-
mune complexes and autoantigens to the bone marrow occurs in
patients withmarginal zone lymphoma. Abnormally expanded gd T
cells could also provide increased amounts of T helper cells to B
cells to produce autoantibodies9. Type 1 gastrointestinal carcinoid
tumors are associated with type 1 chronic atrophic gastritis,
achlorhydria, and pernicious anemia, while only one case has been
reported in ES5. An association between carcinoid and other non-
carcinoid malignancies has been reported in up to 22% of cases10.
Moreover, the coexistence of NET and mucosa-associated lymphoid
tissue lymphoma in the gastrointestinal tract was also reported in
the literature suggesting a common etiology (i.e.,Helicobacter pylori
infection)11e13. In our case, the presence of multiple possible trig-
gers for ES could be synergistic and explain, at least in part, the slow
rise of platelet counts and the resistance to medical treatment.
Accordingly, all triggers are very critical points in advancing
age14,15.
In conclusion, the possibility of age-related multiple comor-
bidities with ES should not be neglected. It is therefore necessary
for a thorough work-up in a newly diagnosed ES patient, and a
more accurate search of miscellaneous factors, especially in elderly
patients to whom comorbidity may be a mask of the underlying
disease.
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